Immunic (IMUX) Share-based Compensation (2013 - 2026)
Immunic (IMUX) posted Share-based Compensation of $4.5 million for Q1 2026, up 159.11% sequentially from -$7.6 million in Q4 2025, and up 118.71% YoY from $2.0 million in Q1 2025.
Immunic (IMUX) Share-based Compensation (2013 - 2026) Analysis & Trends
Immunic has reported Share-based Compensation for 14 years, with the latest figure at $4.5 million in Q1 2026.
- Quarterly Share-based Compensation rose 118.71% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 billion (down 24.53% YoY) and the FY2024 annual result came in at $448000.0, down 17.65% from the prior year.
- Share-based Compensation improved to $4.5 million in Q1 2026 per IMUX's latest filing, from -$7.6 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.1 billion in Q3 2025 and troughed at -$7.6 million in Q4 2025.
- A 5-year average of $619.2 million and a median of $4.5 million in 2026 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation surged 135.03% in 2023, then sank 99.77% in 2025.
- Over 5 years, Share-based Compensation stood at $1.9 million in 2022, then jumped by 43113.15% to $815.0 million in 2023, then plunged by 100.75% to -$6.1 million in 2024, then dropped by 23.97% to -$7.6 million in 2025, then soared by 159.11% to $4.5 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $4.5 million, -$7.6 million, and $2.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Immunic | 682.77 Mn | 682.77 Mn | - | 6.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.78 Mn |
| Jun 30, 2026 | 6.78 Mn |
| Mar 31, 2026 | 4.47 Mn |
| Mar 31, 2026 | 4.47 Mn |
| Dec 31, 2025 | -7.56 Mn |
| Dec 31, 2025 | -7.56 Mn |
| Sep 30, 2025 | 2.08 Bn |
| Sep 30, 2025 | 2.08 Bn |
| Jun 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | 1.90 Mn |
| Mar 31, 2025 | 2.04 Mn |
| Mar 31, 2025 | 2.04 Mn |
| Dec 31, 2024 | -6.09 Mn |
| Dec 31, 2024 | -6.09 Mn |
| Sep 30, 2024 | 1.91 Bn |
| Sep 30, 2024 | 1.91 Bn |
| Jun 30, 2024 | 842.00 Mn |
| Jun 30, 2024 | 842.00 Mn |
| Mar 31, 2024 | 2.75 Mn |
| Mar 31, 2024 | 2.75 Mn |